Evidence map›Paper›PMID 30941561›Full record

SynthesisWorld journal of urology2020

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

A Offermann, M C Hupe, V Sailer, A S Merseburger, S Perner

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

A OffermannInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
M C HupeDepartment of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
V SailerInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
A S MerseburgerDepartment of Urology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
S PernerInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. sven.perner@uksh.de.

Funding

University of Luebeck unknown
6 · The paper itself

Abstract

purposeTo systematically and comprehensively review and summarize the most recent literature assessing the value of the new grading system introduced by the International Society of Urological Pathology (ISUP) in 2014 and accepted by the World Health Organization (WHO) in 2016.

methodsA systematic literature search in the PubMed database was performed up to November 2018. Overall, 15 studies in the period from 2016 to 2018 evaluating the new grading system have been selected for evidence synthesis.

resultsThe main goals of the new ISUP 2014/WHO 2016 grading system were to establish (I) a more accurate and simplified grade stratification, (II) less overtreatment of indolent prostate cancer as well as (III) an improved patient communication. The majority of the studies chose biochemical recurrence as an endpoint for evaluation and statistically assigns the new ISUP 2014/WHO 2016 grading system a higher prognostic accuracy than the former Gleason grading. However, in only a subset of studies it was clearly evident that the historical samples were not only re-grouped according to the new grade groups but also re-graded according to the new histomorphological 2014 ISUP criteria.

conclusionsThe vast majority of the studies support an improved prognostic accuracy of the ISUP 2014/WHO 2016 grade groups and endorse its worldwide application.

Indexed as

Practice Guidelines as TopicAdenocarcinomaHumansKallikreinsMaleNeoplasm GradingNeoplasm Recurrence, LocalPrognosisProstate-Specific AntigenProstatic NeoplasmsWorld Health OrganizationKallikreinsKLK3 protein, humanProstate-Specific AntigenGrade groupInternational Society of Urological Pathology (ISUP)PrognosisProstate cancerWorld Health Organization (WHO)

Identifiers

PMID30941561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.